Bill
SB 2745
SB 2745 would add anxiety disorders and sleep disorders as qualifying medical cannabis conditions under Mississippi's Medical Cannabis Act.
SB 2745 — Mississippi Medical Cannabis Act; amendment to include anxiety and sleep disorders
Overview
- Bill number: SB 2745
- Title: Mississippi Medical Cannabis Act; amend to add anxiety and sleep disorders as debilitating medical conditions
- Status: Died in Committee (no final passage)
- Introduced: March 13, 2025
- Subject: Public Health and Welfare
- Classification: bill
Purpose and intent
- The bill seeks to expand the eligibility for medical cannabis under the Mississippi Medical Cannabis Act by adding two new debilitating medical conditions: anxiety disorders and sleep disorders. If enacted, qualifying patients suffering from these conditions could potentially access medical cannabis under the state program, consistent with the Act’s framework for other listed conditions.
Key provisions (as introduced)
- Amends the Mississippi Medical Cannabis Act to include:
- Anxiety disorders as a debilitating medical condition eligible for medical cannabis
- Sleep disorders as a debilitating medical condition eligible for medical cannabis
- (Note: The bill would operate within the existing structure of Mississippi’s medical cannabis program, which governs patient qualification, physician recommendations, cultivation/dispensing, and regulatory oversight. Specific text beyond the condition-addition is not provided in the summary.)
Who would be affected
- Patients diagnosed with anxiety disorders and sleep disorders who seek access to medical cannabis under Mississippi’s program
- Medical professionals authorizing qualifying patients
- Dispensaries, cultivators, and other participants in the state medical cannabis market
- State regulatory agencies responsible for implementing, monitoring, and enforcing the program
Procedural history and timeline
- Jan 20, 2025: Referred to Public Health and Welfare
- Feb 4, 2025: Died in Committee (preventing advancement in session)
- Mar 13, 2025: Received by the Secretary of the Senate; Filed
- Apr 3, 2025: Read first time; Referred to Business & Commerce
Note: Despite subsequent actions, the bill’s status remains Died In Committee, meaning it did not progress to a floor vote or enactment in this session.
Potential impact and considerations
- If enacted, the bill could broaden patient access to medical cannabis by recognizing anxiety and sleep disorders as qualifying conditions, potentially increasing demand for medical cannabis products and affecting program administration, physician training, and regulatory oversight.
- Practical considerations include ensuring appropriate safeguards, payer/access considerations, and monitoring for safety and efficacy within the expanded eligibility.
- As with all medical cannabis legislation, ongoing federal-state considerations and policy debates about medical use and regulation would continue to influence implementation.
Next steps
- With the bill currently dead in committee, there is no immediate path to enactment in its current form. It could be reintroduced or amended in a future legislative session.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
